

Edge Therapeutics, Inc.  
Form 4  
March 15, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**LOUGHLIN JAMES J**

(Last) (First) (Middle)

200 CONNELL DRIVE, SUITE  
1600

(Street)

BERKELEY HEIGHTS, NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Edge Therapeutics, Inc. [EDGE]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/11/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |       |   |                             |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|-------|---|-----------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |       |   |                             |
| Common Stock                    | 03/11/2016                           |  | P                              |   | 100   | A  | \$ 7.575                          | 100   | I | Family Trust <sup>(1)</sup> |
| Common Stock                    | 03/11/2016                           |  | P                              |   | 13  | A  | \$ 7.627                          | 113   | I | Family Trust <sup>(1)</sup> |
| Common Stock                    | 03/11/2016                           |  | P                              |   | 500   | A  | \$ 7.639                          | 613   | I | Family Trust <sup>(1)</sup> |
| Common Stock                    | 03/11/2016                           |  | P                              |   | 1,107   | A  | \$ 7.6385                         | 1,720 | I | Family Trust <sup>(1)</sup> |
| Common Stock                    | 03/11/2016                           |  | P                              |   | 600   | A  | \$ 7.6385                         | 2,320 | I | Family Trust <sup>(1)</sup> |

Edgar Filing: Edge Therapeutics, Inc. - Form 4

|                 |            |   |     |   |          |        |   |                                |
|-----------------|------------|---|-----|---|----------|--------|---|--------------------------------|
| Common<br>Stock | 03/11/2016 | P | 500 | A | \$ 7.627 | 2,820  | I | Family<br>Trust <sup>(1)</sup> |
| Common<br>Stock | 03/11/2016 | P | 180 | A | \$ 7.627 | 3,000  | I | Family<br>Trust <sup>(1)</sup> |
| Common<br>Stock |            |   |     |   |          | 19,625 | D |                                |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Bene<br>Own<br>Follo<br>Repor<br>Trans<br>(Instr |
|---|--|---|---|--------------------------------------|--|--|---|---|---|
|   |  |   |   |                                      |  | Date<br>Exercisable  | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares                                      |
|   |  |   |   |                                      |  | Code   | V (A) (D)   |   |   |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| LOUGHLIN JAMES J<br>200 CONNELL DRIVE, SUITE 1600<br>BERKELEY HEIGHTS, NJ 07922 |               | X         |         |       |

## Signatures

|   |            |
|---|------------|
| /s/ Albert N. Marchio II,<br>attorney-in-fact | 03/15/2016 |
| <u>    </u> **Signature of Reporting Person   | Date       |

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.